Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs LIVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIVN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

LIVN Overall Winner 6-Pillar Tally: UFPT 3 – 3 LIVN Matrix Metrics: UFPT 4 – 6 LIVN

As of Nov 16, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas LIVN carries 32.7/100 (SELL) at $92.44 (19.5x Forward P/E, 14.3% operating margin).

  • Composite vs. Pillar Nuance: While UFPT currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. LIVN 32.7/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 15.4% operating margin) and revenue trajectory (+9.9% vs. +11.6% YoY).
  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile LIVN trades in a Markup technical trend (BREAKOUT options phase, RSI 66.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs LIVN
UFPT NASDAQ
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
LIVN NASDAQ Head-to-Head Winner
LivaNova PLC Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$92.44
+1.23% 1D
Market Cap $5.0B
TTM Revenue $1.51B
Forward P/E 19.5x
Beta / 30D Vol 1.02β · 67% Vol
Unified Composite Score
32.7 / 100 SELL
Tech 5.0 Fund 25.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 67
RSI-14: 66.8 · SMA20: $85.30 · SMA50: $80.53

6-Pillar Scorecard Institutional Category Breakdown (UFPT 3 – 3 LIVN)

Columns: Metric · UFPT · LIVN
1. Valuation Multiples LIVN
Forward P/E 24.7x 19.5x
Trailing P/E 31.2x 26.2x
PEG Ratio 3.80x 0.93x
EV / Revenue 3.6x 3.2x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% +9.9%
Earnings Growth (YoY) +25.1% -78.2%
TTM Revenue (USD) $650M $1.51B
Market Cap $2.4B $5.0B
3. Profitability & Quality UFPT
Gross Margin 28.9% 67.6%
Operating Margin 15.4% 14.3%
Net Profit Margin 11.8% 13.0%
Return on Equity (ROE) 17.2% 15.5%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) $120M EBITDA $129M
Cash Flow Margin 18.5% EBITDA Mgn 8.6%
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $206M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LIVN
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 42.3% (3rd %ile) 57.7% (17th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat LIVN
OpEx & R&D Intensity 13.5% of Rev ($88M) 53.3% of Rev ($803M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (4) vs LIVN (6)
Institutional Metric UFPT LIVN Criterion Row Edge
Market Capitalization
Scale
$2.4B $5.0B Larger Scale LIVN
Trailing P/E Ratio
Valuation
31.2x 26.2x Lower Multiple LIVN
Forward P/E Ratio
Valuation
24.7x 19.5x Lower Multiple LIVN
Revenue Growth (YoY)
Growth
+11.6% +9.9% Higher Growth UFPT
Operating Margin (TTM)
Profitability
15.4% 14.3% Higher Margin UFPT
Net Profit Margin
Profitability
11.8% 13.0% Higher Margin LIVN
Return on Equity (ROE)
Capital Efficiency
17.2% 15.5% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 85% ($52–$99) Stronger Trend LIVN
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 1.02β · 67% Vol Lower Realized Risk LIVN
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 32.7 / 100 (SELL) Higher Composite UFPT
Trailing 12M Revenue (USD)
Operating Scale
$650M $1.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 67.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev 0.93x PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) $129M ($206M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LIVN +16.79 pp
UFPT: +2.36% · LIVN: +19.15%
3M Horizon LIVN +20.67 pp
UFPT: -4.92% · LIVN: +15.75%
6M Horizon UFPT +9.46 pp
UFPT: +37.44% · LIVN: +27.98%
1Y Horizon LIVN +40.04 pp
UFPT: +27.42% · LIVN: +67.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs LIVN. Trailing 12-month operating profitability (UFPT 15.4% vs LIVN 14.3%) and valuation multiples (UFPT 24.7x vs LIVN 19.5x Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
LIVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.51B
Gross Margin67.6%
Op. Margin14.3%
ROE / Fwd P/E15.5% · 19.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVN BREAKOUT
94d in phase · OBV NEUTRAL
Current IV 57.7%
IV Percentile 17th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
LIVN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.0B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 53.3% of Rev ($803M)
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs LIVN Key Questions & Quantitative Answers

As of Nov 16, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas LIVN carries 32.7/100 (SELL) at $92.44 (19.5x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While UFPT currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. LIVN 32.7/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 15.4% operating margin) and revenue trajectory (+9.9% vs. +11.6% YoY). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile LIVN trades in a Markup technical trend (BREAKOUT options phase, RSI 66.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with LIVN at +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $1.51B for LIVN. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 53.3% of Rev ($803M) (0 disclosures) for LIVN.

LIVN screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas LIVN trades at 19.5x Forward P/E, 26.2x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus LIVN (15.5% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, LIVN carries 57.7% implied volatility (17th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.02β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.